In connection with a presentation at the Swedish Shareholders' Association on 17 November in Vimmerby, Kancera communicates new results in the ROR project. These results indicate that the company's ROR inhibitors may work against a particular type of intractable...
Read MoreKancera AB (publ) announced today that Niclas Brynne has been appointed to lead Kancera's clinical development projects. He will be part of the management team and report directly to the CEO.
Read MoreKancera reports that the Fractalkine antagonist KAN0440567 is able to eliminate pain resulting from inflammation of the pancreas and that the ROR inhibitor KAN0439834 has been shown to effectively kill resistant cancer cells from the bone marrow of multiple...
Read MoreDue to positive efficacy data in disease models of cancer and pain, Kancera's Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project.
Read MoreKancera reports that ROR inhibitors have been tested against human triple negative breast cancer transferred to zebrafish. The experiments showed that Kancera's small molecule ROR inhibitors are able to both reduce tumor size and metastases (spread) of this aggressive...
Read MoreKancera reported that the company has developed a new series of ROR inhibitors that show improved pharmaceutical properties which will allow preclinical studies of their effect on e.g. solid tumors. These results have prompted Kancera to concentrate the investments...
Read MoreKancera's patent covering small molecule inhibitors of PFKFB3 has been approved in the United States. Further, a patent application covering new chemical series in the HDAC6 project has been filed according to plan. In the ROR project, the company...
Read MoreKancera hereby provides an operational update on the PFKFB3 and HDAC6 projects as well as the EU-funded epigenetically targeted parasitic project A-PARADDISE.
Read MoreIn connection with a meeting arranged by the Swedish Shareholders' Association in Malmö on September 30, Kancera provides an operational update on the ROR and Fractalkine projects.
Read MoreKancera has entered into an agreement with Acturum Life Science AB in order to evaluate and further develop the unique Fractalkine inhibitor AZD8797. Published research points to that Fractalkine signaling probably contributes to the growth and spread of tumors...
Read More